Brainomix, a medical imaging startup, has raised £4.8 million in a Series C extension led by Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, with participation from Modi Ventures. The extension adds to the £14 million secured in March 2025, bringing the total in the round to £18.8 million. The additional capital will enable expansion in the U.S. market and support deployment of its imaging platforms across hospitals.
It develops imaging software for stroke and lung fibrosis that helps clinicians analyse scans and make treatment decisions. Its Brainomix 360 Stroke platform supports acute stroke assessment throughout the patient pathway, while e-Lung applies CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. These tools are designed to support clinical decision-making and improve patient triage, treatment selection, and care coordination.
With existing operations in the U.S. and an extensive portfolio of FDA-cleared imaging solutions, the funding will support expansion of customer support across the U.S. and Europe and further integration of its technology into clinical workflows.
Founded as a spinout from the University of Oxford, it operates in more than 20 countries and maintains offices in the UK, Ireland, and the USA.
This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.
Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes. We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes.
